BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC.
Lim SM, et al.
Ther Adv Med Oncol. 2024 Oct 21;16:17588359241280689. doi: 10.1177/17588359241280689. eCollection 2024.
Ther Adv Med Oncol. 2024.
PMID: 39444426
Free PMC article.